Is Sermorelin Legal in Georgia? Federal Law, State Rules, and How to Get a Prescription

What Sermorelin Is and Why Its Legal Status Is Complicated

Sermorelin acetate is a synthetic 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to produce and secrete growth hormone through a mechanism that preserves the body's own feedback loops, unlike direct recombinant human growth hormone (rhGH) administration. The pituitary still controls the pulse, which is why sermorelin is classified as a growth hormone secretagogue rather than a growth hormone itself.

The 2008 Market Withdrawal

Sermorelin was originally sold under the brand name Geref by Serono Pharmaceuticals. The FDA approved Geref for the treatment of idiopathic growth hormone deficiency in children in 1990. Serono voluntarily withdrew Geref from the U.S. Commercial market in 2008 for business reasons, not because of a safety finding. The FDA's own documentation confirms this distinction. A voluntary market withdrawal for commercial reasons is legally different from a safety-based withdrawal or a drug being placed on a "never-compound" list. That difference is the foundation of sermorelin's current legal availability through compounding.

Where It Sits on the FDA Bulks Lists

The FDA maintains lists of bulk drug substances that may or may not be used in compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Sermorelin does not appear on the 503A "Category 1" list of substances withdrawn from the market for safety or effectiveness reasons, which would prohibit compounding. This means licensed 503A pharmacies may compound sermorelin for patient-specific prescriptions, provided all other conditions of the law are met. Prescribers and patients should confirm with their compounding pharmacy that the pharmacy's most recent compliance review still supports sermorelin, because FDA administrative positions on bulk substances can change with relatively short notice periods.

Federal Compounding Law: 503A vs. 503B

Understanding the two compounding pathways clarifies exactly how sermorelin reaches patients legally.

503A: Patient-Specific Compounding

Section 503A of the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act of 2013, governs traditional compounding pharmacies that prepare medications for individual patients based on a valid prescription from a licensed practitioner. Key requirements include:

• A licensed prescriber-patient relationship must exist before the prescription is written.
• The compounded drug must not be essentially a copy of a commercially available FDA-approved product. Because the brand-name Geref is no longer on the market, this restriction does not apply to sermorelin.
• The pharmacy must comply with USP standards for sterile compounding (USP Chapter 797) when preparing injectable formulations.
• The substance must not appear on the FDA's list of bulk substances that may not be used in compounding.

The FDA's framework for 503A compounding is codified in 21 U.S.C. § 503A and has been clarified in multiple agency guidance documents. Sermorelin injections fall under USP 797 sterile compounding rules because they are parenteral preparations.

503B: Outsourcing Facilities

Section 503B covers FDA-registered outsourcing facilities that may produce larger batches without patient-specific prescriptions but that face more rigorous federal oversight, including Current Good Manufacturing Practice (cGMP) inspections. Some telehealth platforms source sermorelin from 503B facilities for operational efficiency. The FDA publishes a registry of registered outsourcing facilities at accessdata.fda.gov. Patients receiving sermorelin through a telehealth service should ask whether their pharmacy is 503A or 503B registered to understand which oversight framework applies.

Georgia State Law and the Board of Pharmacy

Georgia has no statute that independently bans sermorelin. The state follows the federal compounding framework and adds its own professional licensing layer on top of it.

Georgia State Board of Pharmacy Rules

The Georgia State Board of Pharmacy regulates all pharmacies dispensing to Georgia patients, including out-of-state mail-order compounders shipping to Georgia addresses. The Board requires that any pharmacy compounding sterile preparations, such as sermorelin injections, comply with USP Chapter 797 standards. Georgia pharmacy regulations are found under the Georgia Code Title 26, Chapter 4, and the Board's administrative rules at Chapter 480-35. These rules do not enumerate a list of prohibited peptides beyond what federal law already restricts. Physicians and pharmacies operating in Georgia are therefore governed primarily by federal 503A/503B standards plus general state pharmacy practice standards.

The Georgia Composite Medical Board

Physicians, nurse practitioners, and physician assistants who prescribe sermorelin in Georgia are licensed and disciplined by the Georgia Composite Medical Board. The Board's authority to discipline a prescriber rests on Georgia Code § 43-34-8, which covers professional misconduct and practicing outside the standard of care. Prescribing sermorelin outside a legitimate clinical relationship, without appropriate history and physical examination, or without documented evidence of a clinical indication, could expose a practitioner to disciplinary action. There is no Georgia Composite Medical Board rule that prohibits prescribing sermorelin specifically. The standard of care, not a per se ban, governs prescribing decisions.

Out-of-State Mail-Order Pharmacies Shipping to Georgia

Many patients in Georgia receive compounded sermorelin from out-of-state pharmacies licensed in states with historically active compounding industries, such as Florida or Texas. Under federal law and Georgia Board of Pharmacy guidance, an out-of-state pharmacy must hold a valid non-resident pharmacy permit issued by the Georgia Board of Pharmacy to ship prescription medications, including compounded sermorelin, to a Georgia address. Patients should confirm their pharmacy holds this permit before filling a prescription.

Clinical Basis for Prescribing Sermorelin in Georgia

A prescription for sermorelin in Georgia requires a documented clinical indication. Prescribers typically order sermorelin based on evidence of adult growth hormone deficiency (AGHD) or age-related decline in GH secretion. The clinical evidence supporting this use includes data from endocrine and aging research.

Adult Growth Hormone Deficiency

The Endocrine Society's 2011 clinical practice guideline on growth hormone deficiency in adults, updated in subsequent position statements, recognizes AGHD as a diagnosable condition associated with reduced quality of life, adverse body composition changes, and metabolic dysfunction. The guideline states: "Adults with GHD have reduced quality of life, increased fat mass, reduced lean body mass, reduced bone mineral density, and adverse cardiovascular risk factors." [1] Sermorelin, by stimulating endogenous GH secretion, addresses some of these parameters without the regulatory burden associated with direct recombinant GH prescribing.

Published Efficacy Data

A double-blind, placebo-controlled study published in the Journal of Clinical Endocrinology and Metabolism (Walker RF et al., 1994, N=89) found that nightly subcutaneous sermorelin at doses of 0.5 mg produced statistically significant increases in IGF-1 levels compared to placebo over 6 months, with P<0.01 for the primary endpoint. [2] A later study by Vittone et al. Published in Metabolism (1997) involving 47 healthy older men showed that six months of GHRH analogue administration increased lean body mass by 1.5 kg compared to placebo and improved sleep quality as measured by polysomnography, with P<0.05 for lean mass. [3]

A 2019 review in Frontiers in Endocrinology summarizing secretagogue research in aging noted that GHRH analogues including sermorelin restore pulsatile GH secretion more physiologically than exogenous rhGH and carry a lower risk of IGF-1 supraphysiologic elevation, which is a recognized adverse effect of direct rhGH therapy. [4]

IGF-1 Monitoring and Safety

Practitioners prescribing sermorelin in Georgia should measure serum IGF-1 at baseline and at approximately 90 days after initiation. The Endocrine Society guideline recommends maintaining IGF-1 within the age-adjusted reference range during any GH-axis therapy. [1] Blood glucose should also be monitored, because GH-axis stimulation can reduce insulin sensitivity. The FDA safety data associated with the original Geref approval noted glucose intolerance as a potential adverse effect, consistent with the known pharmacology of GH. [5]

How to Get Sermorelin Legally in Georgia

The process for obtaining sermorelin legally in Georgia involves three sequential steps: clinical evaluation, valid prescription, and licensed pharmacy dispensing.

Step 1: Clinical Evaluation

A patient in Georgia must establish a legitimate prescriber-patient relationship before receiving a sermorelin prescription. This means a licensed Georgia MD, DO, NP, or PA must take a history, review symptoms consistent with low GH or AGHD, and either order or review baseline labs including fasting IGF-1, fasting insulin, metabolic panel, and a standard hormone panel. Telehealth visits meet this requirement in Georgia provided the prescriber is licensed in Georgia and the visit complies with the Georgia Telehealth Act (O.C.G.A. § 33-24-56.4) and the Georgia Composite Medical Board's telehealth guidance, which permit synchronous audio-video consultations for initiating new medications.

Step 2: Valid Prescription

The prescription must include the patient's name and address, date, drug name and strength (e.g., sermorelin acetate 9 mg/3 mL), dosing instructions, quantity, and the prescriber's DEA number and Georgia medical license number. Sermorelin is not a DEA-scheduled substance, so a DEA number is required on the prescription for identification purposes rather than controlled-substance authorization. Many compounding pharmacies also require that the prescriber attest the patient has been evaluated clinically and that the compounded preparation is medically necessary.

Step 3: Licensed Compounding Pharmacy

The pharmacy dispensing sermorelin must be registered with the Georgia Board of Pharmacy (if out-of-state, it must hold a non-resident permit) and must comply with USP Chapter 797 for sterile preparations. The National Association of Boards of Pharmacy (NABP) accreditation through its Compounded Sterile Preparations (CSP) program is an additional marker of quality that patients and prescribers may use when selecting a pharmacy. NABP publishes a searchable list of accredited pharmacies at nabp.pharmacy. Patients should avoid any pharmacy or website selling sermorelin without requiring a prescription, because that model violates both federal law and Georgia pharmacy law and represents a significant patient-safety concern.

Sermorelin vs. Other Growth Hormone Secretagogues: Legal Distinctions That Matter in Georgia

Several peptides are grouped loosely with sermorelin in discussions of GH optimization, but their legal statuses differ in ways that matter for Georgia patients and prescribers.

Ipamorelin and CJC-1295

Ipamorelin and CJC-1295 (with or without the drug affinity complex modification) are growth hormone secretagogue receptor (GHSR) agonists, not GHRH analogues. In 2023 and 2024, the FDA placed both on its list of bulk drug substances that may not be used in compounding under 503A and 503B, citing concerns about clinical need and safety data. [6] This means ipamorelin and CJC-1295 cannot currently be legally compounded for patients in Georgia or any other state, in contrast to sermorelin, which remains eligible. Prescribers who previously offered combination protocols (e.g., sermorelin plus ipamorelin) must now review whether those protocols remain compliant.

Tesamorelin

Tesamorelin (Egrifta SV) is an FDA-approved GHRH analogue indicated specifically for HIV-associated lipodystrophy. Because a commercially available approved version exists, it cannot be compounded under the "essentially a copy" restriction of 503A. Sermorelin does not have this barrier because Geref is no longer commercially available.

Recombinant Human Growth Hormone

Direct recombinant HGH products (somatropin; brand names Genotropin, Humatrope, Norditropin, Saizen, and others) are FDA-approved and DEA-regulated under the Anabolic Steroid Control Act only in certain misuse contexts, but prescribing rhGH for anti-aging or body composition purposes without an approved indication is explicitly addressed by the FDA's enforcement priorities. The Endocrine Society's position statement cautions against prescribing rhGH for healthy adults without confirmed AGHD diagnosis. [1] Sermorelin sidesteps this specific regulatory concern by acting indirectly.

Telehealth Sermorelin Prescribing in Georgia: What the Law Requires

Georgia expanded its telehealth framework substantively in 2020 with amendments to O.C.G.A. § 33-24-56.4. Prescribing sermorelin via telehealth in Georgia is permitted provided:

1. The prescriber holds an active Georgia medical license (or an applicable compact license if a multi-state compact applies).
2. A synchronous audio-video visit is conducted before the initial prescription.
3. The prescriber documents a clinical indication supported by history, symptom assessment, and lab review.
4. Follow-up monitoring, including IGF-1 reassessment, is scheduled and documented.

The Georgia Composite Medical Board has not issued a sermorelin-specific telehealth restriction. General telehealth prescribing standards apply. Asynchronous-only (questionnaire-based) prescribing without a live clinical encounter does not meet the Georgia standard for initiating a new prescription medication and should be avoided by compliant telehealth platforms.

Risks of Obtaining Sermorelin Outside the Legal Framework

Patients who purchase sermorelin from international online vendors, domestic research-chemical websites, or non-pharmacy sources bypass every quality and safety control built into the 503A/503B system. Published FDA warning letters to illegal peptide vendors, available at fda.gov, document repeated findings of incorrect concentration, microbial contamination, and absence of the labeled active ingredient in products sold outside the pharmacy system. [7]

An injectable product that has not been prepared under USP 797 sterile compounding conditions presents genuine infection risk, including bacteremia and injection-site abscess. The FDA's MedWatch adverse event database includes reports of serious infections associated with non-pharmacy peptide injections. Patients in Georgia should treat any sermorelin product that arrived without a prescription and without pharmacy labeling as an unregulated substance, not a medication.

What Georgia Patients Should Ask Their Provider

Before starting sermorelin, a Georgia patient should confirm the following with their prescriber:

• Is the prescriber licensed in Georgia and familiar with AGHD diagnostic criteria per Endocrine Society guidelines?
• Has a baseline IGF-1 level been measured and documented?
• Is the compounding pharmacy registered with the Georgia Board of Pharmacy or holding a valid non-resident permit?
• Does the pharmacy hold NABP CSP accreditation or equivalent quality certification?
• Is a 90-day follow-up IGF-1 recheck scheduled?
• Has the prescriber reviewed the current FDA bulk substance list to confirm sermorelin remains eligible for 503A compounding at the time of prescribing?

These questions are not formalities. They are the practical checklist that separates a legally and clinically sound sermorelin protocol from one that carries regulatory or safety risk.